- Home
- WYHG vs MNOV Comparison
WYHG vs MNOV Comparison
Compare WYHG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- MNOV
- Stock Information
- Founded
- WYHG 1915
- MNOV 2000
- Country
- WYHG China
- MNOV United States
- Employees
- WYHG N/A
- MNOV N/A
- Industry
- WYHG
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- MNOV Health Care
- Exchange
- WYHG NYSE
- MNOV Nasdaq
- Market Cap
- WYHG 69.0M
- MNOV 68.2M
- IPO Year
- WYHG 2024
- MNOV 2005
- Fundamental
- Price
- WYHG $1.18
- MNOV $1.33
- Analyst Decision
- WYHG
- MNOV Strong Buy
- Analyst Count
- WYHG 0
- MNOV 2
- Target Price
- WYHG N/A
- MNOV $7.00
- AVG Volume (30 Days)
- WYHG 55.8K
- MNOV 41.6K
- Earning Date
- WYHG 08-15-2025
- MNOV 08-07-2025
- Dividend Yield
- WYHG N/A
- MNOV N/A
- EPS Growth
- WYHG N/A
- MNOV N/A
- EPS
- WYHG 0.20
- MNOV N/A
- Revenue
- WYHG $147,996,867.00
- MNOV N/A
- Revenue This Year
- WYHG N/A
- MNOV N/A
- Revenue Next Year
- WYHG N/A
- MNOV N/A
- P/E Ratio
- WYHG $4.37
- MNOV N/A
- Revenue Growth
- WYHG 19.02
- MNOV N/A
- 52 Week Low
- WYHG $1.10
- MNOV $1.12
- 52 Week High
- WYHG $12.00
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- MNOV 52.39
- Support Level
- WYHG N/A
- MNOV $1.24
- Resistance Level
- WYHG N/A
- MNOV $1.50
- Average True Range (ATR)
- WYHG 0.00
- MNOV 0.06
- MACD
- WYHG 0.00
- MNOV 0.02
- Stochastic Oscillator
- WYHG 0.00
- MNOV 41.38
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The main categories of products are cured meat products, including cured pork sausages, cured pork meat and other cured meat products, such as cured chicken, cured duck and cured fish; snack products, including ready-to-eat sausages, jerky, duck necks, duck feet and claypot rice; and frozen meat products, including frozen sausages, frozen beef patties and frozen chicken breast fillets.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.